Tagged with market access,

Denmark As Denmark and Europe enter a pivotal phase for healthcare and life sciences, Søren Granhøj Pedersen, Managing Director of MSD Denmark & Iceland, offers timely insights into how one of the world’s leading pharmaceutical companies is adapting and contributing. Drawing on a career shaped by international experience and cross-functional leadership,…

Denmark Christof Bischoff, Country Director of AstraZeneca Denmark, draws on over two decades of international and national experience to navigate one of Europe’s most advanced yet complex healthcare environments. In this interview, he reflects on the affiliate’s evolution from a traditional commercial operation to a system-oriented partner driving innovation across clinical…

Denmark Steve Wright, General Manager of Boehringer Ingelheim Denmark and Norway, shares insights on how the company is advancing its ambitious pipeline and aligning with Denmark’s national healthcare priorities. In this interview, Wright discusses Boehringer Ingelheim’s strategic focus on innovation, access, and prevention, while reflecting on the company’s evolving role in…

Switzerland Bairbre Hickie, General Manager at Takeda, discusses the company’s strategic priorities in Switzerland, focusing on its commitment to bringing innovative treatments to patients and its role in advancing the life sciences ecosystem. In this interview, Hickie explores Takeda’s approach to partnerships, its focus on rare diseases and oncology, and how…

Mexico Valued at USD 7.28 billion, the Mexican pharma market stands out within Latin America, ranking second only to Brazil, and registering a solid compound annual growth rate of six percent according to a 2023 CANIFARMA and INEGI study. That makes it, on paper, appear a highly attractive sector for investment,…

Global A new book by two pharma industry experts offers the first truly global perspective on the complexities of market access.   Even the most innovative drug is useless if patients cannot afford or access it. As pharmaceutical innovation advances, market access strategies – determining who gets a drug, at what…

Global Merck KGaA’s Marco Rauland and Kaushal Kishore examine how artificial intelligence and machine learning can best be applied in pharmaceutical pricing and market access. Noting the significant uptake of such tools in other aspects of the pharma value chain, Rauland and Kishore speculate how they might come to revolutionise pricing…

Middle East & Africa Within the context of the MEA region’s maturing regulatory environment, the expansion of healthcare coverage and regulatory changes aimed at making the New Molecular Entities (NMEs) review process more efficient, registrations have increased in Saudi Arabia, UAE, Tunisia and Egypt, but slowed down in other territories. Results from the second…

Global Merck Group’s Vice President Global Market Access & Pricing Strategic Planning, Marco Rauland, takes a look at recent advancements in Machine Learning and Artificial Intelligence and how these technologies can offer a sophisticated and flexible approach not only to predicting drug pricing, but also to estimating market access with different…

Switzerland Marcel Plattner, president of Swiss industry association vips discusses pricing, market access and innovation, as well as the continuing attractiveness of Switzerland as a pharmaceutical investment destination.   Attractive conditions must be maintained both for the large pharmaceutical companies – which are well established in Switzerland, but for which the…

Belgium Veronique Walsh, General Manager of Bristol Myers Squibb (BMS) – Benelux, explains her ambition to build a new company culture following the acquisition of Celgene. Walsh also lays bare the prospects for bringing innovation to Belgian patients and explains how BMS continues to deliver on its promise of transforming lives…

USA Jorge Alderete, president of ALK Americas, outlines the Danish mid-cap’s strategy in the challenging US market, including innovative market access initiatives, and how future models of patient-doctor interaction and medical distribution will look.   Affordability is key. We recently launched a specialty pharmacy network for our portfolio. This allows us…